2 patents currently held
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2036. from the record
Of the 15 now held by other companies, 5 name Regeneron Pharmaceuticals Inc. as their current owner, and 10 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2036
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends May 2036 · High confidence
Also notable
Ends no later than Mar 2039 · Medium confidence
Modified Antibodies and Related Compounds, Compositions, and Methods of Use
US 10,781,259
Granted 2020. Computed term ends 2036.
Compositions and Methods for the Depletion of CD117+ Cells
US 11,958,908
Granted 2024. Too new for citation comparison; protection runs to 2039. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Formerly held, still cited
Notable
Ends Sep 2034 · High confidence
Cited by 10 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2034.
now held by Sensei Biotherapeutics, Inc.
Also notable
Ends Apr 2038 · High confidence
The most cited patent in this portfolio, cited by 11 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
now held by Edigene Biotechnology, Inc.
Also notable
Ends Mar 2039 · High confidence
Cited by 7 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2039.
now held by Crispr Therapeutics AG
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 16, 2027The maintenance fee for Compositions and Methods for the Depletion of CD117+ Cells (US 11,958,908) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 1 term has ended since Aug 23, 2026
- Oct 30 US 10,111,966 Methods for the Depletion of CD117+ Cells · lapsed on the fee record
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions and Methods for the Depletion of CD117+ Cells | 1 in force | to Mar 2039 |
| Modified Antibodies and Related Compounds, Compositions, and Methods of Use | 1 in force | to May 2036 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,781,259 | Modified Antibodies and Related Compounds, Compositions, and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,958,908 | Compositions and Methods for the Depletion of CD117+ Cells In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 2: 15 patents in force now held by others · 2 patents ended · 6 applications pending · 38 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed